Genomic sequencing is essential to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments, vaccines, and guide public health responses. To investigate the global SARS-CoV-2 genomic surveillance, we used sequences shared via GISAID to estimate the impact of sequencing intensity and turnaround times on variant detection in 189 countries. In the first two years of the pandemic, 78% of high-income countries sequenced >0.5% of their COVID-19 cases, while 42% of low- and middle-income countries reached that mark. Around 25% of the genomes from high income countries were submitted within 21 days, a pattern observed in 5% of the genomes from low- and middle-income countries. We found that sequencing around 0.5% of the cases, with a turnaround time <21 days, could provide a benchmark for SARS-CoV-2 genomic surveillance. Socioeconomic inequalities undermine the global pandemic preparedness, and efforts must be made to support low- and middle-income countries improve their local sequencing capacity.

Background In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). Aim This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. Methods We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. Results We estimate B.1.1.7 had a transmission fitness advantage of 43–52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07–1.41] from 01 January until 17 January 2021 and 1.18 [1.06–1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00–1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. Conclusion The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2–3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.

Perennial ryegrass (Lolium perenne L.) is widely used for forage production in both permanent and temporary grassland systems. To increase yields in perennial ryegrass, recent breeding efforts have been focused on strategies to more efficiently exploit heterosis by hybrid breeding. Cytoplasmic male sterility (CMS) is a widely applied mechanism to control pollination for commercial hybrid seed production and although CMS systems have been identified in perennial ryegrass, they are yet to be fully characterized. Here, we present a bioinformatics pipeline for efficient identification of candidate restorer of fertility (Rf) genes for CMS. From a high-quality draft of the perennial ryegrass genome, 373 pentatricopeptide repeat (PPR) genes were identified and classified, further identifying 25 restorer of fertility-like PPR (RFL) genes through a combination of DNA sequence clustering and comparison to known Rf genes. This extensive gene family was targeted as the majority of Rf genes in higher plants are RFL genes. These RFL genes were further investigated by phylogenetic analyses, identifying three groups of perennial ryegrass RFLs. These three groups likely represent genomic regions of active RFL generation and identify the probable location of perennial ryegrass PPR-Rf genes. This pipeline allows for the identification of candidate PPR-Rf genes from genomic sequence data and can be used in any plant species. Functional markers for PPR-Rf genes will facilitate map-based cloning of Rf genes and enable the use of CMS as an efficient tool to control pollination for hybrid crop production.

In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now coined B.1.1.7. Based on the UK data and later additional data from other countries, a transmission advantage of around 40-80% was estimated for this variant. In Switzerland, since spring 2020, we perform whole genome sequencing of SARS-CoV-2 samples obtained from a large diagnostic lab (Viollier AG) on a weekly basis for genomic surveillance. The lab processes SARS-CoV-2 samples from across Switzerland. Based on a total of 7631 sequences obtained from samples collected between 14.12.2020 and 11.02.2021 at Viollier AG, we determine the relative proportion of the B.1.1.7 variant on a daily basis. In addition, we use data from a second lab (Dr Risch) screening all their samples for the B.1.1.7 variant. These two datasets represent 11.5 % of all SARS-CoV-2 confirmed cases across Switzerland during the considered time period. They allow us to quantify the transmission advantage of the B.1.1.7 variant on a national and a regional scale. Taking all our data and estimates together, we propose a transmission advantage of 49-65% of B.1.1.7 compared to the other circulating variants. Further, we estimate the effective reproductive number through time for B.1.1.7 and the other variants, again pointing to a higher transmission rate of B.1.1.7. In particular, for the time period 01.01.2021-17.01.2021, we estimate an average reproductive number for B.1.1.7 of 1.28 [1.07-1.49] while the estimate for the other variants is 0.83 [0.63-1.03], based on the total number of confirmed cases and our Viollier sequencing data. Switzerland tightened measures on 18.01.2021. A comparison of the empirically confirmed case numbers up to 20.02.2021 to a very simple model using the estimates of the reproductive number from the first half of January provides indication that the rate of spread of all variants slowed down recently. In summary, the dynamics of increase in frequency of B.1.1.7 is as expected based on the observations in the UK. Our plots are available online and constantly updated with new data to closely monitor the changes in absolute numbers.

10The recent outbreak of a new coronavirus that causes a Severe Acute Respiratory Syndrome in humans 11 (SARS-CoV-2) has developed into a global pandemic with over 6 million reported cases and more than 12 375,000 deaths worldwide. Many countries have faced a shortage of diagnostic kits as well as a lack 13 of infrastructure to perform necessary testing. Due to these limiting factors, only patients showing 14 symptoms indicating infection were subjected to testing, whilst asymptomatic individuals, who are 15 widely believed to be responsible for the fast dispersion of the virus, were largely omitted from the 16 testing regimes. The inability to implement high throughput diagnostic and contact tracing strategies 17 has forced many countries to institute lockdowns with severe economic and social consequences. The 18World Health Organization (WHO) has encouraged affected countries to increase testing capabilities 19 to identify new cases, allow for a well-controlled lifting of lockdown measures, and prepare for future 20 outbreaks. Here, we propose HiDRA-seq, a rapidly implementable, high throughput, and scalable 21 solution that uses NGS lab infrastructure and reagents for population-scale SARS-CoV-2 testing. This 22 method is based on the use of indexed oligo-dT primers to generate barcoded cDNA from a large 23 number of patient samples. From this, highly multiplexed NGS libraries are prepared targeting SARS-24CoV-2 specific regions and sequenced. The low amount of sequencing data required for diagnosis 25 allows the combination of thousands of samples in a sequencing run, while reducing the cost to 26 approximately 2 CHF/EUR/USD per RNA sample. Here, we describe in detail the first version of the 27 protocol, which can be further improved in the future to increase its sensitivity and to identify other 28 respiratory viruses or analyze individual genetic features associated with disease progression. 29 30